At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 237 enrolled
Drug / intervention
GSK 1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age or Older With Solid Tumours Receiving Chemotherapy
In Brief
A Phase 3 clinical trial evaluating GSK 1437173A and Placebo for Herpes Zoster and Herpes Zoster Vaccine. Completed, enrolled 237 participants across 28 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster, Herpes Zoster Vaccine
CountriesCanada, Czechia, France, South Korea, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartMar 2013
Primary CompletionJun 2015
Study CompletionMay 2016
TodayJul 2026
First PostedFeb 25, 2013
Enrollment StartMar 6, 2013
Primary CompletionJun 18, 2015
Study CompletionMay 20, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.4 years ago
Interventions
GSK 1437173Abiological
2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Placebodrug
2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.